PMID- 23097265
OWN - NLM
STAT- MEDLINE
DCOM- 20130405
LR  - 20220316
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 119
IP  - 5
DP  - 2013 Mar 1
TI  - Long-term follow-up of haploidentical hematopoietic stem cell transplantation 
      without in vitro T cell depletion for the treatment of leukemia: nine years of 
      experience at a single center.
PG  - 978-85
LID - 10.1002/cncr.27761 [doi]
AB  - BACKGROUND: Many patients who require allogeneic hematopoietic stem cell 
      transplantation (allo-HSCT) lack a human leukocyte antigen (HLA)-matched donor. 
      Recently, a new strategy was developed for HLA-mismatched/haploidentical 
      transplantation from family donors without in vitro T cell depletion (TCD). 
      METHODS: Over the past 9 years, 756 patients underwent haploidentical 
      transplantation using a protocol developed by the authors, which combines 
      granulocyte-colony stimulating factor-primed bone marrow (G-BM) and peripheral 
      blood stem cells without in vitro TCD. The long-term outcome with this treatment 
      modality was reported, and a risk-factor analysis was provided. RESULTS: Of these 
      patients, 752 (99%) achieved sustained, full donor chimerism. The incidence of 
      grades 2 through 4 acute graft-versus-host disease (GVHD) was 43%, and the 2-year 
      cumulative incidence of total chronic GVHD was 53%. The 3-year cumulative 
      incidence of nonrelapse mortality was 18%. The 2-year cumulative incidences of 
      relapse were 15% and 26% in the standard-risk and high-risk groups, respectively. 
      Of the 756 patients, 480 survived throughout the follow-up period of 1154 days 
      (range: 335-3511 days) with the 3-year leukemia-free survival rates of 68% and 
      49% in the standard-risk and high-risk groups, respectively. Lower leukemia-free 
      survival was associated with high-risk disease status (P = .001), chronic 
      myelogenous leukemia disease type (P = .004), neutrophil engraftment beyond 13 
      days after transplant (P = .012), and the occurrence of grades 2 through 4 acute 
      GVHD (P = .019). CONCLUSIONS: The results from the authors' 9-year experience 
      showed that G-BM combined with peripheral blood stem cells from haploidentical 
      donors, without in vitro TCD, is a reliable source of stem cells for 
      transplantation by using the protocol developed by the authors.
CI  - Copyright (c) 2012 American Cancer Society.
FAU - Wang, Yu
AU  - Wang Y
AD  - Institute of Hematology, Peking University People's Hospital, Xicheng District, 
      Beijing, China.
FAU - Liu, Dai-Hong
AU  - Liu DH
FAU - Liu, Kai-Yan
AU  - Liu KY
FAU - Xu, Lan-Ping
AU  - Xu LP
FAU - Zhang, Xiao-Hui
AU  - Zhang XH
FAU - Han, Wei
AU  - Han W
FAU - Chen, Huan
AU  - Chen H
FAU - Chen, Yu-Hong
AU  - Chen YH
FAU - Wang, Feng-Rong
AU  - Wang FR
FAU - Wang, Jing-Zhi
AU  - Wang JZ
FAU - Sun, Yu-Qian
AU  - Sun YQ
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121023
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Transfusion/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/immunology
MH  - HLA Antigens
MH  - *Haplotypes
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Histocompatibility
MH  - Humans
MH  - Leukemia/*therapy
MH  - Lymphocyte Depletion
MH  - Male
MH  - Middle Aged
MH  - Transplantation Chimera
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/10/26 06:00
MHDA- 2013/04/06 06:00
CRDT- 2012/10/26 06:00
PHST- 2012/04/28 00:00 [received]
PHST- 2012/06/11 00:00 [revised]
PHST- 2012/06/29 00:00 [accepted]
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2013/04/06 06:00 [medline]
AID - 10.1002/cncr.27761 [doi]
PST - ppublish
SO  - Cancer. 2013 Mar 1;119(5):978-85. doi: 10.1002/cncr.27761. Epub 2012 Oct 23.